Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Apellis Pharmaceuticals (APLS) delivered earnings and revenue surprises of +139.30% and +33.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?